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CC chemokine receptor 2 (CCR2) is one of 19 members of the chemokine receptor subfamily of 
human Class A G protein-coupled receptors (GPCRs). CCR2 is expressed on monocytes, 
immature dendritic cells and T cell subpopulations, and mediates their migration towards 
endogenous CC chemokine ligands such as CCL21. CCR2 and its ligands are implicated in 
numerous inflammatory and neurodegenerative diseases2 including atherosclerosis, multiple 
sclerosis, asthma, neuropathic pain, and diabetic nephropathy, as well as cancer3. These disease 
associations have motivated numerous preclinical studies and clinical trials4 (see 
ClinicalTrials.gov) in search of therapies that target the CCR2:chemokine axis. To aid drug 
discovery efforts5, we solved a structure of CCR2 in a ternary complex with an orthosteric 
(BMS-6816) and allosteric (CCR2-RA-[R]7) antagonist. BMS-681 inhibits chemokine binding by 
occupying the orthosteric pocket of the receptor in a previously unseen binding mode. CCR2-RA-
[R] binds in a novel, highly druggable pocket that is the most intracellular allosteric site observed 
in Class A GPCRs to date; this site spatially overlaps the G protein-binding site in homologous 
receptors. CCR2-RA-[R] inhibits CCR2 non-competitively by blocking activation-associated 
conformational changes and formation of the G protein-binding interface. The conformational 
signature of the conserved microswitch residues observed in double-antagonist-bound CCR2 
resembles the most inactive GPCR structures solved to date. Like other protein:protein 
interactions, receptor:chemokine complexes are considered challenging therapeutic targets for 
small molecules, and the present structure suggests diverse pocket epitopes that can be exploited to 
overcome drug design obstacles.
Main
A ternary complex between an engineered construct of human CCR2 isoform b (further 
referred to as CCR2-T4L or simply CCR2), an orthosteric antagonist BMS-681 (compound 
13d in6), and an allosteric antagonist CCR2-RA-[R]7 was crystallized using the lipidic cubic 
phase method8, and the structure was determined to 2.8 Å resolution (Extended Data Table 1 
and Extended Data Fig. 1). Simultaneous addition of two compounds dramatically stabilized 
detergent-solubilized CCR2-T4L in comparison with twice the concentration of each 
compound individually (Fig. 1a), suggesting concurrent binding of CCR2-RA-[R] and 
BMS-681 to the receptor. The presence of both compounds was critical for crystallization.
In the structure, CCR2 adopts the canonical fold of class A GPCRs with seven 
transmembrane (TM) helices connected by three extracellular (EC) and three intracellular 
(IC) loops (Fig. 1b). Both compounds are visible (Fig. 1b–d); BMS-681 binds in the 
extracellular orthosteric pocket (Fig. 1b, c) while CCR2-RA-[R] is located more than 30Å 
away (Fig. 1b, d), in a site that is the most intracellular allosteric pocket observed in Class A 
GPCRs to date (Fig 1e). The binding site of CCR2-RA-[R] spatially overlaps with the G 
protein-binding site in homologous receptors (Fig 1f). As for other chemokine receptors9–12, 
CCR2 is expected to have two conserved disulfide bonds in its extracellular domains, with 
Cys32-Cys277 connecting the N-terminus (NT) to ECL3, and Cys113-Cys190 connecting 
TM3 to ECL2. Electron density is apparent for the ECL2-TM3 disulfide bond but not for the 
NT residues 1–36 or the NT-ECL3 disulfide bond (Fig. 1b, c). Because the NT-ECL3 
disulfide bond has been shown important for CCR2 signaling13, its absence is unlikely to be 
an inherent feature of the receptor; instead, it might be caused by strain of the bond in the 
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ligand-bound state of the receptor14, possibly exacerbated by solvent exposure and radiation 
damage of the crystals15.
As with other chemokine receptors, the extracellular orthosteric pocket of CCR2 can be 
divided into a major and a minor subpocket, defined by helices III–VII and helices I–III, 
VII, respectively, and separated by residues Y1203.32 and E2917.39 (superscript indicates 
residue number as per Ballesteros-Weinstein nomenclature). BMS-681 binds predominantly 
in the minor subpocket (Fig. 2a,b) and buries 366.3 Å2 of surface area. The 6-
trifluoromethyl quinazoline moiety protrudes between helices I and VII towards the lipid 
bilayer, while the tri-substituted cyclohexane packs against W982.60. The γ-lactam 
secondary exocyclic amine forms a hydrogen bond with the hydroxyl of T2927.40, which is 
critical for binding of chemically related compounds such as BMS-558 (compound 22 in 16) 
and the Teijin lead series17,18. This amine is also within hydrogen bonding distance from the 
backbone carbonyl of Q2887.36. The carbonyl oxygen of the γ-lactam forms a hydrogen 
bond with Y491.39, which itself is hydrogen-bonded to the side chain of T2927.40. The N1 
nitrogen of the quinazoline is within 4 Å of the Q2887.36 side chain. The protonated tertiary 
amine on the cyclohexane ring is proximal to a structured water molecule in the binding site. 
Some CCR2 antagonists, particularly those containing a basic amine, are known to depend 
on the conserved E2917.39 in the receptor19; however, no direct interaction is observed 
between E2917.39 and BMS-681. The receptor-bound, bioactive conformation of BMS-681 
is strikingly similar to the crystallographic conformation of free BMS-681 (Fig. 2c, 
Extended Data Table 2) suggesting the absence of internal strain in the bound state.
BMS-681 engages several residues that are critical for CCL2 binding and/or activation of 
CCR217,18 including Y491.39, W982.60, Y1203.32, and T2927.40. Thus, it seems to directly 
compete with chemokine binding to the orthosteric pocket. Additionally, by inserting 
between helices I and VII, BMS-681 may put strain onto residues C32-V37 connecting TM1 
to ECL3, destabilize the conserved NT-ECL3 disulfide bond (absent in the structure), and 
prevent the N-terminus and TM1 from adopting a productive chemokine binding 
conformation observed in homologous receptor:chemokine structures11,12 (Extended Data 
Fig. 2).
On the opposite side of the receptor, CCR2-RA-[R] is caged by the intracellular ends of 
helices I–III and VI–VIII and buries 297.8 Å2 of surface area. The inner hydrophobic part of 
the cage is made by V631.53, L671.57, L812.43, L1343.46, A2416.33, V2446.36, I2456.37, 
Y3057.53, and F3128.50, while the outer (cytosol-facing) polar part consists of T772.39, 
R1383.50, G3098.47, K3118.49, and Y3158.53 (Fig. 2d, e), as well as the backbones of 
engineered R2376.29 and K2406.32. The binding pocket of CCR2-RA-[R] is highly enclosed 
and possesses a balanced combination of hydrophobic and polar features, all of which favors 
pocket “druggability”5. Owing to the lack of a side-chain on G3098.47, the hydroxyl and 
pyrrolone carbonyl groups of CCR2-RA-[R] can hydrogen-bond to the exposed backbone 
amides of E3108.48, K3118.49, and F3128.50 (Fig. 2d, e). The acetyl group of the compound 
resides near the terminal amine of K3118.49. The critical roles of V2446.36, Y3057.53, 
K3118.49, and F3128.50 in CCR2-RA-[R] binding were established by an earlier mutagenesis 
study20. Because homologs of several residues in the CCR2-RA-[R] binding pocket directly 
couple to the G protein in bovine rhodopsin21 and the β2 adrenergic receptor (β2AR)22 
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structures (Extended Data Fig. 3), CCR2-RA-[R] appears to sterically interfere with G 
protein binding to CCR2.
The structure suggests an interesting symmetric mechanism for the concurrent antagonistic 
action of the two compounds. BMS-681 interferes with chemokine binding directly and with 
G protein coupling indirectly, by stabilizing an inactive, presumably G protein-
incompatible6 conformation of the receptor. Conversely, CCR2-RA-[R] directly prevents G 
protein coupling and allosterically inhibits binding of the CCL2 chemokine23, which, like 
most GPCR agonists, requires an active, G protein-associated receptor for high affinity 
binding23. Bi-directional allosteric communication between the extra- and intracellular sides 
of the receptor is reminiscent of that previously observed in adenosine A2A receptor 
(AA2AR)24 and β2AR25 using allosteric inverse agonist antibodies/nanobodies that target the 
same epitope as CCR2-RA-[R]. Similar to these antibodies, CCR2-RA-[R] was previously 
shown to allosterically enhance, and to be allosterically enhanced by, binding of orthosteric 
antagonists23, i.e. to demonstrate positive binding cooperativity.
We further characterized this cooperativity by studying the binding of BMS-681 to WT 
CCR2 and the crystallization construct CCR2-T4L using previously characterized 
radioactive probes [3H]-INCB-334423 (orthosteric) and [3H]-CCR2-RA (allosteric). In 
equilibrium competition binding assays on WT CCR2, both INCB-3344 and CCR2-RA-[R] 
displaced their homologous radioligand with IC50 values of 17 and 13 nM, respectively 
(Extended Data Fig. 4a, b and Extended Data Table 3), comparable to previously reported 
values23. Compared to WT CCR2, the affinity of both antagonists towards CCR2-T4L was 
improved by approximately 2-fold, suggesting a slight engineering-related shift towards the 
inactive state. BMS-681 fully displaced [3H]-INCB-3344 with nanomolar affinities for both 
constructs, but did not displace [3H]-CCR2-RA. Instead, at 1 μM concentration it enhanced 
the binding of [3H]-CCR2-RA by >30% (Extended Data Fig. 4a, b and Extended Data Table 
3).
In kinetic radioligand experiments, the presence of BMS-681 also increased total binding of 
[3H]-CCR2-RA to both WT CCR2 and CCR2-T4L, with the increase as high as 62% in the 
case of CCR2-T4L (Extended Data Fig. 4c–d, and Extended Data Table 4). 1μM BMS-681 
decreased the dissociation rate constant of [3H]-CCR2-RA, while producing a slight increase 
(WT CCR2) or no change (CCR2-T4L) in the observed association rate constants. 
Moreover, in CCR2-T4L, the presence of BMS-681 changed the biphasic dissociation 
profile of [3H]-CCR2-RA to monophasic, suggesting stabilization of the receptor population 
in a homogenous conformational state (Extended Data Table 4). Along with the stability and 
equilibrium binding data, these results further corroborate the hypothesis that BMS-681 and 
CCR2-RA-[R] cooperatively stabilize a preferred inactive conformation of CCR2-T4L.
We next analyzed the structure of double-antagonist-bound CCR2-T4L to better understand 
this conformation. The plethora of existing class A GPCR structures suggests a conserved 
conformational signature of an active receptor state26. This signature involves separation 
between the intracellular end of helix VI and the rest of the TM bundle, an inward 
repositioning and rotation of helix VII, and concerted repacking of the highly conserved 
microswitches R3.50 (of the DR3.50Y motif), Y5.58, and Y7.53 (of the NPxxY7.53 motif) (Fig. 
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3a, b) to form an intracellular binding interface for G protein. Furthermore, rather than 
adopting either an “on” or “off” state, receptors can occupy an ensemble of intermediate 
conformations27. The active state signature is fully represented in US28, the only agonist-
bound chemokine receptor crystallized to date12 (Fig. 3a–c). By contrast, the double-
antagonist-bound CCR2 structure appears to occupy the opposite end of the activation 
spectrum as it shares the conformational microswitch signatures of the most inactive GPCR 
structures observed thus far (Fig. 3a–e).
As in the inactive CCR5:Maraviroc complex10, the intracellular ends of CCR2 helices III 
and VI are close together, and the conserved R3.50 interacts with D3.49 and T2.39, effectively 
disrupting the G protein binding pocket (Fig. 3b, d, e). Similarly, in both CCR2 and CCR5 
structures, the intracellular end of helix VII is in the inactive outward-facing conformation 
with Y7.53 pointing towards helix II rather than the center of the bundle. However, in CCR5, 
Y5.58 is oriented towards the center of the bundle, whereas in the present CCR2 structure, it 
faces the lipid and is sterically blocked from approaching R3.50 and Y7.53 by F6.38 (Fig. 3d, 
e). The net result of these interactions is that the crystallographically observed conformation 
of CCR2 appears to be even more inactive than that of CCR5 and most similar to dark 
rhodopsin28 and Fab-bound β2AR29. Although receptor construct engineering appears to 
contribute to stabilization of this inactive state, the ligand binding and thermal denaturation 
data suggest that the concerted action of the two antagonists is also important. By directly 
interacting with the conserved activation microswitch residues, CCR2-RA-[R] is perfectly 
positioned to stabilize this inactive state: it sterically blocks Y7.53 from populating the active 
conformation and is propped against R3.50, restricting its orientation away from the G 
protein interface (Fig. 3b). Although located 30 Å away, BMS-681 appears to cooperate with 
CCR2-RA-[R] through their common interactions with helix VII, which moves outward on 
the intracellular side (opposite to its movement during activation) and inward on the 
extracellular side (relative to CCR5 and US28) (Fig. 3f).
The CCR2 structure has general implications for the design of drugs targeting chemokine 
receptors as a family. As with most protein:protein interfaces, the orthosteric binding 
pockets of chemokine receptors are large, wide open, and highly polar. Chemokines explore 
numerous hotspots within these pockets and their binding is additionally reinforced by the 
interaction with the flexible N-termini of the receptors11,12 (Fig. 4a), collectively making for 
an extensive and versatile interaction that is conceptually difficult to inhibit with small 
molecules. The CCR2:BMS-681:CCR2-RA-[R] structure extends the repertoire of ideas that 
can be employed to overcome these obstacles. The binding mode of BMS-681 (Fig. 4b) 
contrasts with both the binding mode of Maraviroc to CCR5 (Fig. 4c) where the ligand spans 
the major and the minor subpocket of the receptor, and that of IT1t to CXCR4 (Fig. 4d) 
where the ligand is entirely accommodated in the minor subpocket. While occupying the 
minor subpocket of CCR2, BMS-681 protrudes between helices I and VII towards the lipid 
bilayer (Fig. 4b) in an interaction facilitated by the trifluoromethyl group that is often 
present in CCR2 antagonists30. This interaction enables hydrophobic anchoring of BMS-681 
to the otherwise polar and open binding site of CCR2; by doing so, it parallels the role of 
other unique non-polar subpockets exploited by crystallized small molecule antagonists of 
CCR5 and CXCR4 (Fig. 4b–d). The novel subpocket explored by BMS-681 may have an 
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additional advantage of disrupting the chemokine-compatible conformation of the receptor 
N-terminus (Extended Data Fig. 2).
CCR2-RA-[R] demonstrates a previously unseen binding mode within an allosteric pocket 
on the intracellular side of CCR2. Although relatively small, this pocket has a desirable 
balance of polarity and hydrophobicity (Fig. 2e and 4e). Homologous pockets may be 
present in other chemokine receptors, owing to a conserved G8.47; in fact, compound 
binding in homologous regions has been indirectly demonstrated for CCR1 and CCR5, and 
directly for CCR431, CXCR1, and CXCR232. In most other receptors that have been 
crystallized thus far, the non-glycine residue at position 8.47 appears to both reduce the 
pocket volume and block access to the backbone amides of helix 8; consequently, the 
homologous pockets in these receptors may not be druggable although negative allosteric 
modulation with antibodies and nanobodies targeting the same region has been reported24,25. 
By simultaneously competing with G protein and blocking activation-related conformational 
changes, compound binding in the allosteric pocket appears a powerful way to antagonize 
the receptor. Therefore, for those receptors in which the allosteric pocket is druggable, 
targeting it with small molecules may open new avenues for GPCR drug discovery.
Methods
Design and Expression of CCR2-T4L fusion constructs
The sequence of human CCR2 isoform b (Uniprot ID P41597-2) was engineered for 
crystallization by truncation of C-terminal residues 329–360 and by grafting T4 lysozyme 
(T4L) into the ICL3. In the process of construct optimization, the native CCR2 residues 
between L2265.62 and R2406.32 (L2265.62-KTLLRCRNEKKRH-R2406.32) were removed 
and replaced with corresponding residues from the crystallized structure of M2 muscarinic 
acetylcholine receptor (PDB ID 3UON, resulting amino-acid sequence S2265.62-RASKSRI-
T4L-PPPSREK-K2406.32). The presence of T4L in ICL3 is expected to prevent receptor 
activation; however the similar affinities of BMS-681 and CCR2-RA-[R] for both WT CCR2 
and CCR2-T4L (Extended Data Fig. 4a,b and Extended Data Table 3) suggest that the fusion 
construct is a good surrogate of WT CCR2 for understanding ligand recognition.
The CCR2-T4L coding sequence was cloned into a modified pFastBac1 vector (Invitrogen) 
with an HA signal sequence followed by a FLAG tag at the N-terminus and a PreScission 
protease site followed by a 10xHis tag and another FLAG tag at the C-terminus. The 
receptor was expressed in Spodoptera frugiperda (Sf9) cells. High-titer recombinant 
baculovirus (>109 viral particles per ml) was obtained using the Bac-to-Bac Baculovirus 
Expression System (Invitrogen) as previously described11. Sf9 cells at a cell density of 2–3 
× 106 cells ml−1 were infected with P1 virus at an MOI (multiplicity of infection) of 5. Cells 
were harvested by centrifugation 48 h post-infection and stored at −80 °C until use.
Purification of CCR2-T4L
Insect cell membranes were prepared by thawing frozen cell pellets in a hypotonic buffer 
containing 10 mM HEPES (pH 7.5), 10 mM MgCl2, 20 mM KCl and EDTA-free complete 
protease inhibitor cocktail tablets (Roche). Extensive washing of the raw membranes was 
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performed by repeated douncing and centrifugation in the same hypotonic buffer (2–3 times) 
and then in a high osmotic buffer containing 1.0 M NaCl, 10 mM HEPES (pH 7.5), 10 mM 
MgCl2, 20 mM KCl and EDTA-free complete protease inhibitor cocktail tablets (3–4 times), 
thereby separating soluble and membrane associated proteins from integral transmembrane 
proteins. 40 mM stock solutions of BMS-681 and CCR2-RA-[R] were made in isopropanol. 
Washed membranes were resuspended into a buffer containing 50 μM BMS-681, 2 mg/ml 
iodoacetamide, and EDTA-free complete protease inhibitor cocktail tablets, and incubated at 
4 °C for 1 h before solubilization. The membranes were then solubilized in 50 mM HEPES 
(pH 7.5), 400 mM NaCl, 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace), 0.2% 
(w/v) cholesteryl hemisuccinate (CHS, Sigma) at 4 °C for 3 h. The supernatant was isolated 
by centrifugation at 50,000g for 30 min, and incubated in 20 mM HEPES (pH 7.5), 400 mM 
NaCl with TALON IMAC resin (Clontech) overnight at 4 °C. After binding, the resin was 
washed without addition of ligands with 10 column volumes of Wash I Buffer (50 mM 
HEPES (pH 7.5), 400 mM NaCl, 10% (v/v) glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 
10 mM imidazole), followed by 4 column volumes of Wash II Buffer (50 mM HEPES (pH 
7.5), 400 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 0.01% (w/v) CHS, 50mM 
imidazole). The protein was then eluted with 3–4 column volumes of Elution Buffer (50 mM 
HEPES (pH 7.5), 1 μM BMS-681, 400 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 
0.01% (w/v) CHS, and 250 mM imidazole). PD MiniTrap G-25 columns (GE Healthcare) 
were used to remove imidazole. The protein was then treated overnight with His-tagged 
PreScission protease to cleave the C terminal His-tag and Flag-tag. PreScission protease and 
the cleaved C-terminal fragment were removed by binding to TALON IMAC resin for 2 h at 
4 °C. The protein was collected as the TALON IMAC column flow-through. The protein 
was supplemented with 75 μM each of BMS-681 and CCR2-RA-[R] before being 
concentrated to 30mg/ml with a 100 kDa molecular weight cut-off Amicon centrifuge 
concentrator (Millipore). The estimated final compound concentrations were ~ 1–2 mM for 
both compounds.
Protein stability assays
The thermostability of CCR2-T4L was analyzed by a differential scanning fluorimetry 
(DSF) assay adapted from previous publications33 using a RotorGene Q 6-plex RT-PCR 
machine (Qiagen). Briefly, 1–5 μg of protein was mixed with 3 μM 7-Diethylamino-3-(4′-
Maleimidylphenyl)-4-Methylcoumarin (CPM) dye (2.5 mM stock in DMSO) in 25 mM 
HEPES pH 7.5, 400 mM NaCl, 0.02% DDM, 0.004% CHS, 10% glycerol, and indicated 
concentrations of compounds to a final volume of 20 μL; samples were incubated for 5 min 
at room temperature and then heated gradually from 28 °C to 90 °C at a rate of 0.8 °C/min, 
with CPM fluorescence (excitation 365 nm, emission 460 nm) recorded every 1 °C. The 
melting temperature (Tm) was determined from the first derivative of the denaturation curve, 
using the Rotor-Gene Q – Pure Detection software (version 2.0.3).
Crystallization
Purified CCR2 in complex with BMS-681 and CCR2-RA-[R] was reconstituted into lipidic 
cubic phase (LCP) by mixing with molten lipid using a mechanical syringe mixer8. The 
protein-LCP mixture contained 40% (w/w) receptor solution, 54% (w/w) monoolein and 6% 
(w/w) cholesterol. Crystallization trials were performed in 96-well glass sandwich plates 
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(Hampton research) using a Mosquito LCP robot (TTP Labtech) by dispensing 45 nL of 
protein-laden LCP and 800 nL of precipitant solution per well. Plates were incubated and 
imaged at 20 °C. Initial crystal hits were found from a precipitant condition containing 100 
mM MES, pH 6.5, 30% (v/v) PEG400, 100 mM Li2SO4. After optimization, diffraction 
quality crystals were obtained from 100 mM MES, pH 6.5, 30–32% (v/v) PEG400, 75–85 
mM Li2SO4. Crystals usually grew to a maximum size of 60 μm × 10 μm × 10 μm in one 
week, and were harvested directly from the LCP matrix using MiTeGen micromounts and 
flash cooled in liquid nitrogen.
Data collection and structure determination
X-ray diffraction data were collected using a 10 μm collimated minibeam at a wavelength of 
1.0332 Å with a Pilatus3 6M direct detector on the 23ID-D beamline (GM/CA CAT) of the 
Advanced Photon Source at the Argonne National Laboratory. Crystals were located and 
aligned by the rastering strategy34. Among the several hundred crystal samples screened, 
most crystals diffracted to 2.8–3.5 Å resolution when exposed to 0.3 s of unattenuated beam 
using 0.3° oscillations. A 93.1% complete data set at 2.80 Å resolution was obtained by 
merging data from 17 crystals, using XDS35 and Aimless36. As the data showed anisotropy, 
the UCLA Diffraction Anisotropy Server (http://services.mbi.ucla.edu/anisoscale/) was used 
to truncate the data to 3.0 Å along both a* and b* axes, and to 2.81 Å along the c* axis. 
Initial phase information was obtained by molecular replacement (MR) with the program 
Phaser37 using the receptor portion of the CCR5 structure (PDB ID: 4MBS) converted to 
polyalanines, and the T4L portion of the CXCR4 structure (PDB ID: 3ODU) as search 
models. The correct MR solution (TFZ=14.8) contained one CCR2-T4L molecule in the 
asymmetric unit. Refinement was performed with Phenix38 followed by manual examination 
and rebuilding of the refined coordinates in the program COOT39 using both |2Fo| - |Fc| and |
Fo| - |Fc| maps, as well as omit maps. The final model includes 295 residues (37 to 225 and 
241–319) of the 360 residues of CCR2 and residues 2 to 161 of T4L plus 16 residues of two 
8-residue linkers. The remaining N- and C-terminal residues are disordered and were not 
built. Strong electron density for one metal ion was observed. The identity of the ion was 
determined to be Zn2+ by X-ray fluorescence scans (Extended Data Fig. 5). The zinc ion is 
coordinated by a water molecule as well as side chains of H1443.56, E238, and E1005. Data 
collection and refinement statistics is shown in Extended Data Table 1.
Crystallization and structure determination of BMS-681
BMS-681 was dissolved in a minimal amount of CH3CN and then 15% water was added. 
After standing overnight, the resulting crystals were harvested. Data were collected on a 
Bruker-AXS X8-Proteum Kappa goniometer and APEXII detector. Intensities were 
measured using Cu Kα radiation (λ = 1.5418 Å) with the crystal kept at a constant 
temperature using an Oxford cryo system during data collection. Indexing and processing of 
the measured intensity data were carried out with the SAINT-APEX2 (Bruker-AXS) 
program suite, structure solution with SHELXS-97 and structure refinement with 
SHELXL-97.
The derived atomic parameters (coordinates and temperature factors) were refined through 
full matrix least-squares. The function minimized in the refinements was Σw (|Fo| - |Fc|)2. R 
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is defined as Σ ||Fo| - |Fc||/Σ |Fo| while Rw = [Σw (|Fo| - |Fc|)2/ Σw |Fo|2]1/2 where w is an 
appropriate weighting function based on errors in the observed intensities. Hydrogens were 
introduced in idealized positions with isotropic temperature factors, but no hydrogen 
parameters were varied. It should be noted that the refinement model illustrates significant 
disorder and partial occupancy factors of ‘guest’ solvent/water molecules within the 
crystalline lattice. The atomic positions of these disordered molecules were taken from the 
difference map analysis, which showed peaks of electron density of varying intensities at the 
refined positions representing the disordered solvent/water molecules. Data collection and 
refinement statistics is shown in Extended Data Table 2.
Cell culture and transfections
Chinese hamster ovary (CHO) cells (provided by Hans den Dulk, Leiden University, The 
Netherlands; originally obtained from and certified by ATCC) were cultured in Dulbecco’s 
Modified Eagle Medium/F-12 Nutrient Mixture (DMEM/F-12) supplemented with 10% 
(v/v) newborn calf serum, 50 IU/mL penicillin and 50μg/mL streptomycin; and maintained 
at 37°C and 5% CO2. Cells were subcultured twice a week at a ratio of 1:30 to 1:50 by 
trypsinization. Transient transfection of CHO cells with WT CCR2 and CCR2-T4L 
constructs was performed using a polyethylenimine (PEI) method, as described previously23. 
Briefly, CHO cells were grown on 15 cm ø to around 50% confluence and then transfected 
with a DNA/PEI mixture containing 10 μg plasmid DNA – previously diluted in 150 mM 
NaCl solution – mixed with PEI solution (1 mg/mL) at a 1:6 DNA:PEI mass ratio. Before 
adding 1 mL of the transfection mixture to each plate, the culture medium of the cells was 
refreshed and the mixture incubated for 20 min at room temperature. Following transfection, 
cells were incubated for 48 h at 37°C and 5% CO2 before membrane preparation. 24 h after 
transfection, sodium butyrate was added to each plate at a final concentration of 3 mM to 
increase receptor expression. CHO cells were tested for mycoplasma contamination before 
use, the outcome of which was negative.
Membrane preparation
Membranes from CHO cells transiently expressing the WT CCR2 or CCR2-T4L were 
prepared as described previously23. Briefly, cells were detached from 15-cm ø plates using 5 
mL of phosphate-buffered saline and centrifuged for 5 min at 3000g. The membranes were 
separated from the cytosolic fractions by several centrifugation and homogenization steps. 
First, the pellets were resuspended and homogenized in ice-cold membrane buffer (50 mM 
Tris-HCl buffer, supplemented with 5 mM MgCl2, pH 7.4) using an Ultra Thurrax 
Homogenizer (IKA-Werke GmbH & Co. KG; Staufen, Germany). Homogenized membranes 
were then centrifuged in an Optima LE-80 K ultracentrifuge (Beckman Coulter, Inc., 
Fullerton, CA) at 31,000g for 20 min at 4°C. The final membrane pellet was resuspended 
also in ice-cold membrane buffer and aliquoted before storage. Membrane aliquots were 
stored at −80°C and protein concentrations were measured using a standard BCA protein 
determination assay (Pierce Chemical Company, Rockford, IL USA).
Radioligand binding assays
[3H]-INCB-3344 (specific activity 32 Ci mmol−1) and [3H]-CCR2-RA (specific activity 63 
Ci mmol−1) were custom-labeled by Vitrax (Placentia, CA). JNJ-27141491 was synthesized 
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as described previously40. INCB-3344 and CCR2-RA-[R] were synthesized in-house as 
described previously7,41.
All radioligand binding assays were performed at 25 °C in a 100 μL reaction volume 
containing assay buffer (50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% CHAPS) and 
30 μg of membrane protein from CHO cells transiently expressing WT CCR2 or CCR2-
T4L. For competition binding assays with [3H]INCB-3344, a concentration of 5 nM 
[3H]INCB-3344 was used, and non-specific binding was determined with 10 μM of 
unlabeled INCB-3344. In the case of [3H]-CCR2-RA competition binding assays, a 
radioligand concentration of 3 nM was used and non-specific binding was determined with 
10 μM of JNJ-27141491. In all cases, homologous or competition displacement assays were 
carried out using six increasing concentrations of competing ligands. Kinetic experiments 
were also performed at 25 °C using 7 nM [3H]-CCR2-RA and 30 μg of membrane protein in 
a 100 μL reaction volume. For association experiments, CHO-CCR2 or CHO-CCR2-T4L 
membranes were added to the reaction at 8 different time points, in the absence or presence 
of 1μM BMS-681. For dissociation experiments, membranes were first incubated with 
radioligand for 90 min, dissociation was then initiated by addition of 10 μM of CCR2-RA-
[R] at 12 different time points, in the presence or absence of 1μM BMS-681. A higher 
number of time points were used in the dissociation assays, in order to characterize the 
biphasic profile of [3H]-CCR2-RA dissociation. In all cases, total radioligand binding did 
not exceed 10% of the total radioligand added to avoid ligand depletion. For all experiments, 
incubation was terminated by dilution with ice-cold wash buffer (50 mM Tris-HCl buffer 
(pH 7.4), 5 mM MgCl2, 0.05% CHAPS). Separation of bound from free radioligand was 
achieved by rapid filtration over a 96-well GF/B filter plate using a Perkin Elmer Filtermate-
harvester (Perkin Elmer, Groningen, the Netherlands) and filter-bound radioactivity was 
determined in a Perkin Elmer 2450 Microbeta2 plate counter after addition of 25 μL 
Microscint scintillation cocktail per well (Perkin-Elmer, Groningen, the Netherlands).
Statistical Methods
All radioligand binding data were analysed using Prism 6.0 and 7.0 (GraphPad software, San 
Diego, CA, USA). The pIC50 values were obtained by non-linear regression analysis of 
competition displacement assays. Apparent association rate constants (kobs) and maximum 
binding (Bmax, used to calculate %B/Bcontrol) were determined by fitting the association data 
to a one-phase exponential association function. Dissociation rate constants were determined 
by fitting the dissociation data to a monophasic (koff) or biphasic (koff,fast and koff,slow) 
exponential decay model. All data shown represent means ± S.E.M of at least three 
independent experiments performed in duplicate. An unpaired, two-tailed Student’s t-test 
was used to compare differences in pIC50 as well as differences in kinetic parameters. 
Differences in binding enhancement (%Binding) in the absence (set at 100%) or presence of 
BMS-681 were analyzed using a one-way ANOVA with Dunnett’s post-hoc test. Significant 
differences are denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001.
Data deposition statement
The atomic coordinates and structure factors for CCR2:BMS-681:CCR2-RA-[R] complex 
have been deposited in the Protein Data Bank under accession number 5T1A. The structure 
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of free BMS-681 is deposited in the Cambridge Crystallographic Data Centre (CCDC) under 
accession number 1479580.
Extended Data
Extended Data Figure 1. CCR2-T4L crystals and crystal packing
a–c, Crystal packing of CCR2-T4L. CCR2 is a blue ribbon with ECL2 colored red and T4L 
yellow. The unit cell is shown as a green box. CCR2-T4L molecules are arranged in a type I 
packing with hydrophilic stacking mediated by T4L and T4L-ECL2 interactions along axis 
c. a, Crystal packing in the ac plane. CCR2 makes abundant hydrophobic contacts with its 
neighbor via an interface mediated by antiparallel helix IV–helix VI interactions related by a 
screw axis along axis a. b, Crystal packing in the bc plane. Contacts between receptors and 
T4L involve ECL2 and the intracellular surface of CCR2 including helix VIII. Direct 
contacts between T4L are along axis b. One layer of CCR2-T4L molecules at the very top of 
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the stacking column are omitted for clarity. c, Crystal packing in the ab plane. There are no 
direct interactions between T4L along axis a. d, Crystals of CCR2-T4L in the LCP bolus. 
Average crystals grew to 60 μm × 10 μm × 10 μm before harvesting.
Extended Data Figure 2. BMS-681 binding may disrupt a chemokine-recognizing conformation 
of the CCR2 N-terminus and helix I
a, Model of CCR2:CCL2 built by homology from the structure of CXCR4:vMIP-II11 
suggests that a productive chemokine-compatible conformation of the receptor requires re-
orientation of the N-terminus from almost parallel to almost perpendicular to the membrane 
plane, and formation of an extra helical turn in helix I to bring it closer to helix VII and 
ECL3. b, Binding of BMS-681 may disrupt this chemokine-compatible conformation by 
inserting between helices I and VII.
Extended Data Figure 3. CCR2-RA-[R] directly binds to CCR2 residues that are homologous to 
those involved in G protein coupling in other GPCRs
Partial alignment of intracellular regions of CCR2 and homologous regions in bovine Rho 
(bRho) and β2 adrenergic receptor (β2AR), alongside profile of contacts that CCR2-RA-[R], 
Zheng et al. Page 12
Nature. Author manuscript; available in PMC 2017 June 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the Gαt C-terminal peptide21, and Gαs C-terminus22 make with the three respective 
receptors. Contacts are shown by circles above and below the alignment, with circle area 
indicative of contact strength. Backbone and side-chain contacts are gray and black, 
respectively. Assuming structural homology between the CCR2:G protein interface and at 
least one of the bRho:Gαt and β2AR:Gαs interfaces, several residue positions appear to be 
involved in binding both CCR2-RA-[R] and the G protein C-terminus.
Extended Data Figure 4. Equilibrium binding and binding kinetics of BMS-681 and CCR2-RA-
[R] with WT CCR2 and CCR2-T4L
a,b, Displacement of [3H]-INCB-3344 (5nM, a) and [3H]-CCR2-RA-[R] (3 nM, b) from 
WT CCR2 and CCR2-T4L in CHO cells by increasing concentrations of unlabeled 
INCB-3344, CCR2-RA-[R] and BMS-681. c, d, Association and e, f, dissociation of 7nM 
[3H]-CCR2-RA from CHO cell membranes transiently expressing WT CCR2 (c, e) or 
CCR2-T4L (d, f) at 25°C, in the absence or presence of 1 μM BMS-681. Figures represent 
normalized and combined data from three independent experiments performed in duplicate, 
with results presented as mean ± S.E.M percentage of specific [3H]-CCR2-RA binding.
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Extended Data Figure 5. A Zn2+ binding site was identified by X-ray fluorescence emission (Xfe) 
analysis of the CCR2-T4L:BMS-681:CCR2-RA-[R] crystals
a, View of the Zn2+ ion at an interface formed by CCR2 helices III and VI and the N-
terminus of T4L. The Zn2+ ion is coordinated by side chains of H1443.56 (from WT 
receptor), E2386.30 (from the engineered part of the receptor), and E1005 (from T4L) as well 
as a structured water. b, The background fluorescence signal of an empty MiTeGen 
micromount is low, indicating the absence of metal ion. Excitation at 12 keV results in a 
peak at 11.7 keV (due to the incidence beam). c, Xfe signal from a wide fluorescence scan 
of the CCR2-T4L crystal. The fluorescence peaks at 8.60 keV and 9.53 keV correspond to 
X-ray emission lines Kα (8.64 keV) and Kβ (9.57 keV) and indicate the presence of Zn2+ 
bound to CCR2-T4L. d, A zoomed-in view of the Xfe signal from (c).
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Extended Data Table 1
Data collection and refinement statistics (molecular replacement)
CCR2-T4L:BMS-681:CCR2-RA-[R]a
Data collectionb wavelength (Å) 1.03319
Space group P212121
Unit cell parameters a,b,c (Å) 59.19 64.69 169.90
Number of reflections measured 82,111
Number of unique reflections 15,550
Resolution (Å) 48-2.8 (2.95-2.8)
Rmerge (%) 22.5(101)
Rpim (%) 12.8(88.4)
Mean I/s(I) 6.9(0.8)
Completeness (%) 93.1(66.6)
Redundancy 5.3(1.8)
Refinement
Resolution (Å) 25-2.81 (3.0, 3.0, 2.81)
Number of reflections (test set) 14515 (746)
Rwork/Rfree 0.227/0.272 (0.319/0.389)
Number of atoms 3,580
CCR2 2,215
T4L 1,243
BMS-681 35
CCR2-RA-[R] 24
Monoolein 25
Sulfate 20
Water 17
Zn 1
Mean overall B value (Å2) 41.4
Wilson B 40.4
Protein 41.5
Ligands 41.3
Water 22.9
Root mean square deviation
Bond lengths (Å) 0.003
Bond angles (°) 0.84
Ramanchandran plot statisticsc (%)
Favored regions 97.3
Allowed regions 2.7
Disallowed regions 0
a
Diffraction data from 17 crystals were merged into a complete data set
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b
Highest resolution shell statistics are shown in parentheses
cAs defined in MolProbity42
Extended Data Table 2
Small Molecule (BMS-681) X-ray data collection and refinement.
Empirical formula C26 H36 F3N 5 O3.58
Formula weight 532.80
Temperature 173(2) K
Wavelength 1.54178 Å
Crystal system Tetragonal
Space group P43212
Unit cell dimensions a = 20.4436(4)Å α= 90°.
b = 20.4436(4)Å β= 90°.
c = 28.9325(7)Å γ = 90°.
Volume 12092.1(4) Å3
Z 16
Density (calculated) 1.171 Mg/m3
Absorption coefficient 0.768 mm−1
F(000) 4522
Crystal size 0.46 × 0.18 × 0.16 mm3
Theta range for data collection 2.65 to 58.78°.
Resolution range 16.7 to 0.9 Å
Index ranges −22 ≤ h ≤ 22, −21 ≤ k ≤ 22, −31 ≤ l ≤ 14
Reflections collected 108743
Independent reflections 8518 [R(int) = 0.1259]
Completeness to theta = 58.78° 98.6 %
Absorption correction None
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 8518 / 22 / 713
Goodness-of-fit on F2 1.058
Final R indices [I>2sigma(I)] R1 = 0.0770, wR2 = 0.2087
R indices (all data) R1 = 0.0860, wR2 = 0.2178
Absolute structure parameter; Flack(x) 0.1(2)
Absolute structure parameter; Hooft(y), P3true 0.03(5), 1.000
Largest diff. peak and hole 0.543 and −0.405 e.Å−3
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Extended Data Table 3
Displacement of specific [3H]-INCB-3344 (5 nM) and [3H]-CCR2-RA (3 nM) binding from 
CCR2 constructs transiently expressed on CHO cells.
[3H]-INCB-3344 
displacement by 
INCB-3344
[3H]-INCB-3344 
displacement by 
BMS-681
[3H]-CCR2-RA 
displacement by 
CCR2-RA-[R]
[3H]-CCR2-RA 
enhancement by 
BMS-681
Construct pIC50 ± S.E.M (IC50, nM) %Binding
WT CCR2 7.8 ± 0.0 (17) 8.1 ± 0.0 (8) 7.9 ± 0.0 (13) 134 ± 3%a **
CCR2-T4L 8.1 ± 0.1* (8) 8.6 ± 0.1** (3) 8.2 ± 0.0** (6) 157 ± 13%a ****
Values represent mean ± S.E.M of at three independent experiments performed in duplicate.
a
Percentage of [3H]-CCR2-RA (3 nM) binding in presence of BMS-681 (1 μM). Values higher than 100% represent 
binding enhancement compared to the 100% control without BMS-681.
Differences in pIC50 values between constructs were analyzed using a Student’s t-test, with significant differences noted as 
follows: *p < 0.05, **p < 0.01.
Differences in %Binding in the absence (100%) and presence of BMS-681 were analyzed using a one-way ANOVA with 
Dunnett’s post-hoc test, with significant differences noted as follows: **p < 0.01, ****p < 0.0001.
Extended Data Table 4
Observed association and dissociation rate constants of [3H]-CCR2-RA (7 nM) on 
membranes from CHO cells transiently expressing WT CCR2 and CCR2-T4L, in the 
absence or presence of 1 μM BMS-681.
CHO-CCR2 CHO-CCR2-T4L
Control +1 μM BMS-681 Control +1 μM BMS-681
kobs(min−1) 0.031 ± 0.002 0.038 ± 0.003* 0.015 ± 0.003 0.015 ± 0.001
%B/Bcontrola 100 ± 0.0 135 ± 2.0**** 100 ± 0.0 162 ± 8.4**
koff,fast (min−1) 0.089 ± 0.015 0.069 ± 0.012* 0.077 ± 0.013
0.049 ± 0.003b
koff,slow (min−1) 0.016 ± 0.005 0.012 ± 0.004 0.010 ± 0.003
%fast 70 ± 10 71 ± 11 69 ±8 N/Ab
Values represent mean ± S.E.M of three independent experiments performed in duplicate.
a% B/Bcontrol represents the % of maximum binding in absence (Bcontrol) or presence (B) of BMS-681 (1 μM).
b
For CHO-CCR2-T4L only, dissociation kinetics of [3H]CCR2-RA (7 nM) in presence of BMS-681 (1 μM) fitted best with 
a monophasic exponential decay model, resulting in a single koff value, as shown in the table. Thus for CHO-CCR2-T4L, 
the statistical significance between koff measurements with and without BMS-681 could not be calculated.
Statistical significance was analyzed using a Student’s t-test, with significant differences versus control noted as follows: *p 
< 0.05, **p < 0.01, ****p<0.0001
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Figure 1. Structure of the CCR2:BMS-681:CCR2-RA-[R] complex and comparison to other 
allosteric modulators of class A GPCRs
a, Thermal denaturation curves demonstrate higher stability of CCR2-T4L in the presence of 
both BMS-681 and CCR2-RA-[R] compared to each compound individually. Data is 
representative of three independent experiments conducted on different days. b, Overall 
view of double-antagonist-bound CCR2. c, d, Structure viewed from the extracellular (c) 
and intracellular (d) side with simulated annealing omit maps of BMS-681 (c) and CCR2-
RA-[R] (d) shown at 3σ. e, CCR2-RA-[R] compared to other allosteric ligands crystallized 
with Class A GPCRs (PDBIDs 4mbs, 4xnv, 4phu, and 4mqt). f, CCR2-RA-[R] compared 
with the C-terminal helix of Gαs bound to the β2 adrenergic receptor and transducin peptide 
bound to rhodopsin (PDBIDs 3sn6 and 4x1h).
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Figure 2. Ligand binding sites and receptor interactions
a,b BMS-681 interactions with CCR2 viewed in 3D from the extracellular side (a) and in a 
2D schematic depiction (b). c, Of the two conformers in the free BMS-681 structure, one is 
almost identical to the CCR2-complexed conformation. d,e CCR2-RA-[R] interactions 
viewed in 3D along the plane of the membrane and from the intracellular side (d), and in a 
2D depiction (e). In (b, e), polar and non-polar residue contacts are shown as blue and green, 
respectively. Bulk solvent and lipid are represented by blue and yellow shading, respectively.
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Figure 3. The crystallographic conformation of double antagonist bound CCR2 has pronounced 
structural signatures of an inactive state
Structures of active (US28, salmon), inactive (CCR5, grey), and apparently more inactive 
(CCR2, blue) chemokine receptors viewed along the plane of the membrane (a) and across 
the membrane from the intracellular side (b–e). b, Overlay of structures; arrows show the 
direction of activation-associated conformational changes; sticks show conserved Y5.58, 
R3.50 and Y7.53; the white mesh is CCR2-RA-[R]. c–e, Detailed, single-receptor depictions 
of (b). (f) Although located ~30 Å apart, the orthosteric (BMS-681, magenta) and the 
allosteric (CCR2-RA-[R], yellow) ligands cooperate in stabilizing an inactive conformation 
of CCR2 through helix VII.
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Figure 4. Structural motifs exploited by small molecule antagonists of chemokine receptors
Receptor surface meshes are colored by polarity (cyan–polar, grey–nonpolar). a, Modeled 
CCR2:CCL2 complex illustrates the extensive receptor:chemokine interface. b–d, Structures 
CCR2:BMS-681 (b), CCR5:Maraviroc (PDBID 4mbs, (c), and CXCR4:IT1t (PDBID 3odu, 
(d). Compounds utilize unique non-polar subpockets (yellow contours) within the open polar 
binding pockets of their target receptors. e, The allosteric pocket possesses a balanced 
combination of hydrophobic and polar features, making it a promising target for drug 
development.
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